Caspofungin Injectable Medication Recalled for Sterility Assurance Issues
Sentara Infusion Services is recalling Caspofungin 50mg injectable bags dispensed nationwide due to lack of sterility assurance. Patients should consult their healthcare provider.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of injectable medication. While sterility assurance issues in injectable drugs present a significant risk of infection, no illnesses or injuries have been reported in the source material. The recall represents a risk-of-harm situation where injury has not yet been reported.
Plain-English summary
Sentara Infusion Services is recalling seven bags of Caspofungin 50mg in normal saline (100ml) that were dispensed to patients nationwide. The medication was administered using a Homepump device.
The recall is due to a lack of sterility assurance, which means the preparation may not meet required sterilization standards. This poses a potential risk of contamination for patients who received this medication. Affected batches have a beyond-use date of December 30-31, 2023.
Patients who received this medication should contact their healthcare provider immediately to discuss whether they were affected and to determine if any medical follow-up is needed.
The recalled product
- Product
- CASPOFUNGIN 50MG IN NS 100ML, used with a HOMEPUMP, Sentara Home Infusion Pharmacy Services, 535 Independence Pkwy, Ste 300, Chesapeake, VA 23320
- Manufacturer
- Sentara Infusion Services
- Category
- Drug — Injectable / Intravenous
- Hazard
- sterility-assurance
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Beyond Use Date: December 30-31
- 2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27